Press Releases US

Intact Vascular Announces Positive One-Year Data from
TOBA II BTK Clinical Trial in VIVA Late-Breaking Session
Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session
Durable Below-the-Knee Vascular Implant for Post-Angioplasty Dissection Repair Demonstrates Sustained Success Saving Limbs

June 25, 2020 WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive one-year results from its Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trial livestream. Co-Principal Investigator, Patrick Geraghty, M.D., Professor of …

Intact Vascular Announces Positive One-Year Data from
TOBA II BTK Clinical Trial in VIVA Late-Breaking Session
Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session
Durable Below-the-Knee Vascular Implant for Post-Angioplasty Dissection Repair Demonstrates Sustained Success Saving Limbs
Read More »

VIVA Late-Breaking Clinical Trial Session to Showcase TOBA II BTK One-Year Data

June 22, 2020 WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the one-year data from its Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial will be presented during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trial event by Co-Principal Investigator, Patrick Geraghty, …

VIVA Late-Breaking Clinical Trial Session to Showcase TOBA II BTK One-Year Data Read More »

Intact Vascular Announces Publication of TOBA III Clinical Trial Results in the Journal of Vascular Surgery
Peer-Reviewed Article Validates Tack Endovascular System® as a Clinically Important Treatment for Post-Angioplasty Dissection Repair in Above-the-Knee Complex Lesions

May 13, 2020 WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the peer-reviewed publication of its Tack Optimized Balloon Angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-center, single-arm, prospective study investigated the combination of the Tack Endovascular …

Intact Vascular Announces Publication of TOBA III Clinical Trial Results in the Journal of Vascular Surgery
Peer-Reviewed Article Validates Tack Endovascular System® as a Clinically Important Treatment for Post-Angioplasty Dissection Repair in Above-the-Knee Complex Lesions
Read More »

Intact Vascular Announces First U.S. Commercial Use of Tack Endovascular System® (4F) in Below-the-Knee Arteries

April 22, 2020 WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® (4F) in multiple sites across the United States. Notably the first FDA-approved vascular implant for below-the-knee post-angioplasty dissection repair, Tack® implants are designed to …

Intact Vascular Announces First U.S. Commercial Use of Tack Endovascular System® (4F) in Below-the-Knee Arteries Read More »

Tack Endovascular System® Receives FDA Approval for Below-the-Knee Post-Angioplasty Dissection Repair
Intact Vascular’s Tack Endovascular System® is a First-of-its-Kind Vascular Implant for Optimized Balloon Angioplasty Outcomes in Challenging CLI Patient Population

April 14, 2020 – WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced it received U.S. Food and Drug Administration (FDA) approval for the Tack Endovascular System (4F), a novel, minimal metal implant for precision dissection repair in the mid/distal popliteal, tibial and/or peroneal arteries. …

Tack Endovascular System® Receives FDA Approval for Below-the-Knee Post-Angioplasty Dissection Repair
Intact Vascular’s Tack Endovascular System® is a First-of-its-Kind Vascular Implant for Optimized Balloon Angioplasty Outcomes in Challenging CLI Patient Population
Read More »

Intact Vascular Expands Tack Endovascular System® Portfolio Offering

January 28, 2020 WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced Food and Drug Administration PMA approval for the expansion of its Tack Endovascular System® (6F) portfolio. The new approved device size is indicated for repair of post-angioplasty dissections in superficial femoral and proximal …

Intact Vascular Expands Tack Endovascular System® Portfolio Offering Read More »

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA ConferenceFirst-of-its-Kind Pivotal Study of the Tack Endovascular System® Demonstrates 100% Dissection Resolution in Challenging Below-the-Knee Disease

November 6, 2019 – WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive six-month results of its Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial, successfully achieving all primary (P < 0.0001) and secondary endpoints with very low rates of major amputation …

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA ConferenceFirst-of-its-Kind Pivotal Study of the Tack Endovascular System® Demonstrates 100% Dissection Resolution in Challenging Below-the-Knee Disease Read More »

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical TrialGrowing Body of Evidence Supporting Use of the Tack Endovascular System®to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD

September 27, 2019 – WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive one-year results of its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial, successfully achieving both primary and secondary endpoints. Marianne Brodmann, M.D., Head of the Clinical Division of Angiology, Medical …

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical TrialGrowing Body of Evidence Supporting Use of the Tack Endovascular System®to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD Read More »

Journal of Endovascular Therapy Publishes Peer Reviewed Article Underscoring the Clinical Impact of Post-Angioplasty DissectionsIntact Vascular’s Tack Endovascular System® is highlighted as a treatment option for post-PTA dissections

June 18, 2019 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today welcomed the peer-reviewed  publication, “Dissections After Infrainguinal Percutaneous Transluminal Angioplasty (PTA): Systematic Review and Current State of Clinical Evidence” currently available online, with the print article scheduled to be published in the August issue …

Journal of Endovascular Therapy Publishes Peer Reviewed Article Underscoring the Clinical Impact of Post-Angioplasty DissectionsIntact Vascular’s Tack Endovascular System® is highlighted as a treatment option for post-PTA dissections Read More »

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

First-of-its-kind study designed to demonstrate safety and efficacy of the Tack Endovascular System® in treating post-PTA dissections  November 6, 2018 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial …

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial Read More »

Scroll to Top
Intact Vascular uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this.